These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19881349)

  • 21. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
    Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
    J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
    Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
    Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on nephrogenic systemic fibrosis.
    Thomsen HS; Marckmann P; Logager VB
    Magn Reson Imaging Clin N Am; 2008 Nov; 16(4):551-60, vii. PubMed ID: 18926421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
    Lind Ramskov K; Thomsen HS
    Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
    [No Abstract]   [Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
    Kadiyala D; Roer DA; Perazella MA
    Am J Kidney Dis; 2009 Jan; 53(1):133-7. PubMed ID: 19022548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis: a review of the new conundrum.
    Goenka AH; Das CJ; Sharma R
    Natl Med J India; 2009; 22(6):302-6. PubMed ID: 20384019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis.
    Thakral C; Abraham JL
    J Cutan Pathol; 2009 Dec; 36(12):1244-54. PubMed ID: 19602073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.